Kinexum

Executive Summary

Kinexum is a US-based regulatory consulting firm with over two decades of experience guiding life sciences companies through complex regulatory pathways at agencies such as the FDA, EMA, and MHRA. Founded in 2003, the company offers comprehensive expertise across regulatory strategy, clinical development, CMC, nonclinical studies, and quality assurance, with a particular focus on metabolic and digital health sectors. As a private consulting firm rather than a drug developer, Kinexum generates revenue through service fees and maintains a relatively stable business model independent of drug approval outcomes. Its deep regulatory knowledge positions it as a valuable partner for innovative therapeutic and digital health companies navigating evolving global regulations.

Upcoming Catalysts (preview)

• Q3 2026FDA final guidance on digital health technologies for metabolic monitoring70% success
• Q4 2026Major partnership with a top-20 pharma company for regulatory strategy services40% success
• Q1 2027Expansion of advisory services to include AI/ML-based drug development regulatory support60% success